Sarah Nikiforow, Jennifer S Whangbo, Ran Reshef, Donald E Tsai, Nancy J Bunin, Rolla F Abu-Arja, Kris Michael Mahadeo, Wen-Kai Weng, Koen Van Besien, David Loeb, Sunita D Nasta, Eneida R Nemecek, Weizhi Zhao, Yan Sun, Faith C Galderisi, Justin Wahlstrom, Aditi Mehta, Laurence Isabelle Gamelin, Rajani Dinavahi, Susan E Prockop
Patients with Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in whom initial treatment fails have few options and historically low median overall survival (OS) of 0.7 months following allogeneic hematopoietic cell transplant (HCT) and 4.1 months following solid organ transplant (SOT). Tabelecleucel is an off-the-shelf, allogeneic EBV-specific cytotoxic T-lymphocyte immunotherapy for EBV+ PTLD. Previous single-center experience showed responses in patients with EBV+ PTLD following HCT or SOT...
April 16, 2024: Blood Advances